In re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation
On February 6, 2024, the court in In re: Seroquel XR (Extended Release Quetiapine Fumarate) Antitrust Litigation, No. 20-1076-CFC, certified a class of persons or entities who directly purchased 50mg, 150mg, 200mg, and/or 300mg strength of brand or generic Seroquel XR tablets between August 2, 2015 and April 30, 2017, and appointed Garwin Gerstein & Fisher LLP lead counsel for the class. Defendants are (a) AstraZeneca Pharmaceuticals L.P., AstraZeneca L.P. (collectively, “AstraZeneca”), (b) Handa Pharmaceuticals, LLC (“Handa”), and (c) Par Pharmaceutical, Inc. (“Par”). Plaintiffs allege that Defendants violated the Sherman Act when AstraZeneca and its generic competitor, Handa, entered into an anticompetitive reverse payment settlement agreement delaying generic competition for Seroquel XR, thereby maintaining the price of Seroquel XR at supra-competitive levels. Par joined the alleged illegal contract, combination and conspiracy in restraint of trade when it acquired the rights to Handa’s generic Seroquel XR. Plaintiffs are seeking damages in the form of overcharges that class members paid to Defendants as a result of the misconduct.
Click document titles to open them.
- Order Granting Direct Purchaser Class Plaintiffs' Motion For Class Certification
- Notice to Class
- Direct Purchaser Class Plaintiffs’ Unopposed Motion for Preliminary Approval of Proposed Settlements, Approval of the Form and Manner of Notice to the Class and Proposed Schedule for a Fairness Hearing
- Brief in Support of Direct Purchaser Class Plaintiffs’ Unopposed Motion for Preliminary Approval of Proposed Settlements, Approval of the Form and Manner of Notice to the Class and Proposed Schedule for a Fairness Hearing
- [Proposed] Order Granting Direct Purchaser Class Plaintiffs’ Unopposed Motion for Preliminary Approval of Proposed Settlements, Approval of the Form and Manner of Notice to the Class and Proposed Schedule for a Fairness Hearing
- Declaration of Jonathan M. Gerstein in Support of Direct Purchaser Class Plaintiffs’ Unopposed Motion for Preliminary Approval of Proposed Settlements, Approval of the Form and Manner of Notice to the Class and Proposed Schedule for a Fairness Hearing
- Settlement Agreement Between AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited and Direct Purchasers
- Settlement Agreement Between Handa Pharmaceuticals, LLC and Direct Purchasers
- Declaration of William W. Wickersham of RG/2 Claims Administration LLC in Support of Direct Purchaser Class Plaintiffs’ Unopposed Motion for Preliminary Approval of Proposed Settlements, Approval of the Form and Manner of Notice to the Class and Proposed Schedule for a Fairness Hearing
- Notice
- Claim Form
- Direct Purchaser Plaintiffs’ Plan of Allocation for the Direct Purchaser Class
- Declaration of Dr. Russell L. Lamb Related to Proposed Settlement Allocation Plan
- Declaration Of Liz Lambert of Huntington National Bank Related to Escrow Agreement
- Order Granting Direct Purchaser Class Plaintiffs' Unopposed Motion For Preliminary Approv Al Of Proposed Settlements, Approval Of The Form And Manner Of Notice To The Class And Proposed Schedule For A Fairness Hearing
- Notice to Class Members
- Claim Form